Please wait a minute...
Journal of Integrative Agriculture  2026, Vol. 25 Issue (7): 2959-2969    DOI: 10.1016/j.jia.2024.12.005
Animal Science · Veterinary Medicine Advanced Online Publication | Current Issue | Archive | Adv Search |
Collateral sensitivity to gamithromycin in ciprofloxacin-resistant Streptococcus suis is driven by increasing intracellular antibiotic accumulation

Yuejun Zhang1, 2, Mengting Tao3, Ruiling Wang1, 2, Zilin Shi1, 2, Peipei Li1, 2, Sijia Tang1, 2, Jian Sun1, 2, 4, Xiaoping Liao1, 2, 4, Yufeng Zhou1, 2, 4#

1 State Key Laboratory of Animal Disease Control and Prevention, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China

2 Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou 510642, China

3 Institute of Laboratory Animal Science, Jinan University, Guangzhou 510632, China

4 Jiangsu Co-Innovation Center for the Prevention and Control of Important Animal Infectious Disease and Zoonosis, Yangzhou University, Yangzhou 225009, China

 Highlights 
A complex network of collateral sensitivity was characterized in Streptococcus suis.
Gamithromycin exhibited collateral sensitivity toward ciprofloxacin-resistant S. suis.
Altered membrane potential and reduced efflux pump activity lead to increased intracellular antibiotic levels.
Elevated intracellular accumulation of gamithromycin contributes to collateral sensitivity in ciprofloxacin-resistant S. suis.
Download:  PDF in ScienceDirect  
Export:  BibTeX | EndNote (RIS)      
摘要  

作为一种重要的人畜共患病原菌,猪链球菌因其对抗生素的多重耐药性以及对猪群和人类健康构成的威胁而日益受到关注迫切需要有效的治疗策略。附属敏感性(collateral sensitivity是指细菌在对一种抗生素产生耐药性同时,对另一种抗生素的敏感性增强的现象,这一机制为应对细菌耐药性的进化提供了新的思路本研究通过实验室诱导成功获得了对11临床常见抗生素耐药的猪链球菌亚群,并详细描绘了抗生素耐药猪链球菌的附属敏感性图谱及其复杂的敏感性关联特征。结果表明,对环丙沙星耐药的猪链球菌在体内外均表现出对加米霉素的显著附属敏感性。同时,加米霉素能有效限制猪链球菌对氟喹诺酮类药物耐药性的进化,并缩小其突变选择窗(mutant selection windows, MSW)的范围。进一步的机制研究揭示,在环丙沙星药物压力下,耐药猪链球菌由于钾离子转运蛋白基因(ktrB和多药外排泵基因pmrA)的突变,导致菌株膜电位的改变和质子动力势(proton-motive force, PMF)依赖的外排泵功能降低,显著增加了抗生素在菌体的胞内积累,并最终导致了对加米霉素的附属敏感性。小鼠大腿感染的体内治疗结果进一步证实,基于附属敏感机制的加米霉素治疗方案对环丙沙星耐药猪链球菌感染具有更好的效、更低的药效学靶值和更高的治疗成功率。综上所述,本研究阐明了加米霉素对环丙沙星耐药猪链球菌产生附属敏感性的机制,为基于附属敏感机制设计耐药猪链球菌感染的治疗方案提供了新的思路。



Abstract  

Streptococcus suis has garnered increasing attention due to its implication in severe infections in both swine and humans, as well as its development of multidrug resistance.  The phenomenon of collateral sensitivity, whereby resistance to one antibiotic leads to increased sensitivity to another, provides new opportunities for mitigating the evolution of resistance.  In this study, we evolved resistance in Ssuis to 11 clinically used antibiotics and characterized the resulting collateral sensitivity profiles, revealing a complex network of interactions.  Based on our findings, we identified dozens of such drug pairs and demonstrated collateral sensitivity to gamithromycin in ciprofloxacin-resistant Ssuis both in vitro and in vivo.  Gamithromycin effectively limits the evolution of resistance and reduces the mutant selection window for ciprofloxacin-resistant Ssuis strains.  Mechanistic studies indicated that the heightened sensitivity of ciprofloxacin-resistant Ssuis to gamithromycin was associated with increased intracellular gamithromycin accumulation due to membrane potential alterations and reduced functions of proton motive force (PMF)-dependent efflux pumps.  Furthermore, collateral sensitivity-based treatments significantly resensitized ciprofloxacin-resistant Ssuis strains to gamithromycin, resulting in superior efficacy, lower pharmacodynamic targets, and higher treatment success rates in a murine thigh infection model.  Our results indicate that gamithromycin sensitivity in Ssuis is a collateral consequence of resistance to ciprofloxacin, providing valuable insight for the strategic design of collateral sensitivity-based antibiotic therapies for Ssuis infections.

Keywords:  collateral sensitivity       S. suis        gamithromycin        ciprofloxacin  
Received: 01 June 2024   Accepted: 22 October 2024 Online: 05 December 2024  
Fund: 

This work was supported by the National Key Research and Development Program of China (2023YFD1800100), the National Natural Science Foundation of China (32172909 and 31902318), the Guangdong Basic and Applied Basic Research Foundation, China (2024A1515010365), the Foundation for Innovative Research Groups of National Natural Science Foundation of China (32121004), the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program, China (2019BT02N054), the Double First-Class Discipline Promotion Project, China (2023B10564003) and the 111 Center, China (D20008). 

About author:  #Correspondence Yufeng Zhou, Tel/Fax: +86-20-85288387, E-mail: zyf@scau.edu.cn

Cite this article: 

Yuejun Zhang, Mengting Tao, Ruiling Wang, Zilin Shi, Peipei Li, Sijia Tang, Jian Sun, Xiaoping Liao, Yufeng Zhou. 2026. Collateral sensitivity to gamithromycin in ciprofloxacin-resistant Streptococcus suis is driven by increasing intracellular antibiotic accumulation. Journal of Integrative Agriculture, 25(7): 2959-2969.

Aulin L B S, Liakopoulos A, van der Graaf P H, Rozen D E, van Hasselt J G C. 2021. Design principles of collateral sensitivity-based dosing strategies. Nature Communications12, 5691.

Cai J, Shi J, Chen C, He M, Wang Z, Liu Y. 2023. Structural-activity relationship-inspired the discovery of saturated fatty acids as novel colistin enhancers. Advanced Science10, e2302182.

Cao M, Feng Y, Wang C, Zheng F, Li M, Liao H, Mao Y, Pan X, Wang J, Hu D, Hu F, Tang J. 2011. Functional definition of LuxS, an autoinducer-2 (AI-2) synthase and its role in full virulence of Streptococcus suis serotype 2. Journal of Microbiology49, 1000–1011.

Chen X W, Wu J H, Liu Y L, Munang’andu H M, Peng B. 2023. Fructose promotes ampicillin killing of antibiotic-resistant Streptococcus agalactiaeVirulence14, 2180938.

CLSI 2020. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals: Approved Standard. 5th ed. Wayne: Clinical and Laboratory Standards Institute (CLSI) Supplement VET01S.

Dong C L, Wu T, Dong Y, Qu Q W, Chen X Y, Li Y H. 2024. Exogenous methionine contributes to reversing the resistance of Streptococcus suis to macrolides. Microbiology Spectrum12, e0280323.

Dong X, Chao Y, Zhou Y, Zhou R, Zhang W, Fischetti V A, Wang X, Feng Y, Li J. 2021. The global emergence of a novel Streptococcus suis clade associated with human infections. EMBO Molecular Medicine13, e13810.

Dou Q, Zhu Y, Li C, Bian Z, Song H, Zhang R, Wang Y, Zhang X, Wang Y. 2023. 4F-indole enhances the susceptibility of Pseudomonas aeruginosa to aminoglycoside antibiotics. Microbiology Spectrum11, e0451922.

Feng Y, Zhang H, Ma Y, Gao G F. 2010. Uncovering newly emerging variants of Streptococcus suis, an important zoonotic agent. Trends in Microbiology18, 124–131.

Feng Y, Zhang H, Wu Z, Wang S, Cao M, Hu D, Wang C. 2014. Streptococcus suis infection. Virulence5, 477–497.

Fuentes-Hernandez A, Plucain J, Gori F, Pena-Miller R, Reding C, Jansen G, Schulenburg H, Gudelj I, Beardmore R. 2015. Using a sequential regimen to eliminate bacteria at sublethal antibiotic dosages. PLoS Biology13, e1002104.

Gianvecchio C, Lozano N A, Henderson C, Kalhori P, Bullivant A, Valencia A, Su L, Bello G, Wong M, Cook E, Fuller L, Neal III J B, Yeh P J. 2019. Variation in mutant prevention concentrations. Frontiers in Microbiology10, 42.

Gonzales P R, Pesesky M W, Bouley R, Ballard A, Biddy B A, Suckow M A, Wolter W R, Schroeder V A, Burnham C A, Mobashery S, Chang M, Dantas G. 2015. Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA. Nature Chemical Biology11, 855–861.

Haenni M, Lupo A, Madec J Y. 2018. Antimicrobial resistance in Streptococcus spp. PLoS Biology6, 10.

Hasan M, Wang J, Ahn J. 2023. Ciprofloxacin and tetracycline resistance cause collateral sensitivity to aminoglycosides in Salmonella typhimuriumAntibiotics12, 1335.

Hernando-Amado S, Sanz-García F, Martínez J L. 2020. Rapid and robust evolution of collateral sensitivity in Pseudomonas aeruginosa antibiotic-resistant mutants. Advanced Science6, eaba5493.

van Hout J, Heuvelink A, Gonggrijp M. 2016. Monitoring of antimicrobial susceptibility of Streptococcus suis in the Netherlands, 2013–2015. Veterinary Microbiology194, 5–10.

Imamovic L, Ellabaan M M H, Dantas Machado A M, Citterio L, Wulff T, Molin S, Krogh Johansen H, Sommer M O A. 2018. Drug-driven phenotypic convergence supports rational treatment strategies of chronic infections. Cell172, 121–134.

Imamovic L, Sommer M O. 2013. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Science Translational Medicine5, 204ra132.

Lázár V, Pal Singh G, Spohn R, Nagy I, Horváth B, Hrtyan M, Busa-Fekete R, Bogos B, Méhi O, Csörgő B, Pósfai G, Fekete G, Szappanos B, Kégl B, Papp B, Pál C. 2013. Bacterial evolution of antibiotic hypersensitivity. Molecular Systems Biology9, 700.

Lee W, Hwang J S, Lee D G. 2015. A novel antimicrobial peptide, scolopendin, from Scolopendra subspinipes mutilans and its microbicidal mechanism. Biochimie118, 176–184.

Li Q, Chen S, Zhu K, Huang X, Huang Y, Shen Z, Ding S, Gu D, Yang Q, Sun H, Hu F, Wang H, Cai J, Ma B, Zhang R, Shen J. 2022. Collateral sensitivity to pleuromutilins in vancomycin-resistant Enterococcus faeciumNature Communications13, 1888.

Liakopoulos A, Aulin L B S, Buffoni M, Fragkiskou E, van Hasselt J G C, Rozen D E. 2022. Allele-specific collateral and fitness effects determine the dynamics of fluoroquinolone resistance evolution. Proceedings of the National Academy of Sciences of the United States of America119, e2121768119.

Liu Y, Jia Y, Yang K, Li R, Xiao X, Zhu K, Wang Z. 2020. Metformin restores tetracyclines susceptibility against multidrug resistant bacteria. Advanced Science7, 1902227.

Liu Y, Tong Z, Shi J, Jia Y, Deng T, Wang Z. 2021. Reversion of antibiotic resistance in multidrug-resistant pathogens using non-antibiotic pharmaceutical benzydamine. Communications Biology4, 1328.

Ma X, Xi W, Yang D, Zhao L, Yu W, He Y, Ni W, Gao Z. 2023. Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniaeDrug Resistance Updates68, 100961.

Mai N T, Hoa N T, Nga T V, Linh L D, Chau T T, Sinh D X, Phu N H, Chuong L V, Diep T S, Campbell J, Nghia H D, Minh T N, Chau N V, de Jong M D, Chinh N T, Hien T T, Farrar J, Schultsz C. 2008. Streptococcus suis meningitis in adults in Vietnam. Clinical Infectious Diseases46, 659–667.

Mei J, Jiang X, Li F, Wu Z, Wu T, Zhu J, Jiang H, Li Z, Li N, Lei L. 2025. Streptococcus suis serotype 2 collagenase-like protease promotes meningitis by increasing blood–brain barrier permeability. Journal of Integrative Agriculture24, 4379-4394.

Pan Z, He P, Zhang Y, Gu Q, Chen S, Yu Y, Shao J, Wang K, Wu Z, Yao H, Ma J. 2022. SssP1, a Fimbria-like component of Streptococcus suis, binds to the vimentin of host cells and contributes to bacterial meningitis. PLoS Pathogens18, e1010710.

Qu Q, Cui W, Huang X, Zhu Z, Dong Y, Yuan Z, Dong C, Zheng Y, Chen X, Yuan S, Li Y. 2023. Gallic acid restores the sulfonamide sensitivity of multidrug-resistant Streptococcus suis via polypharmaceology mechanism. Journal of Agricultural and Food Chemistry71, 6894–6907.

Roemhild R, Andersson D I. 2021. Mechanisms and therapeutic potential of collateral sensitivity to antibiotics. PLoS Pathogens17, e1009172.

Roemhild R, Linkevicius M, Andersson D I. 2020. Molecular mechanisms of collateral sensitivity to the antibiotic nitrofurantoin. PLoS Biology18, e3000612.

Segura M. 2009. Streptococcus suis: An emerging human threat. Journal of Infectious Diseases199, 4–6.

Segura M. 2015. Streptococcus suis vaccines: Candidate antigens and progress. Expert Review of Vaccines14, 1587–1608.

Shi K, Li Y, Xu M, Zhang K, Gou H, Li C, Zhai S. 2024. Membrane vesicles derived from Streptococcus suis serotype 2 induce cell pyroptosis in endothelial cells via the NLRP3/Caspase-1/GSDMD pathway. Journal of Integrative Agriculture23, 1338-1353.

Stautz J, Hellmich Y, Fuss M F, Silberberg J M, Devlin J R, Stockbridge R B, Hänelt I. 2021. Molecular mechanisms for bacterial potassium homeostasis. Journal of Molecular Biology433, 166968.

Szybalski W, Bryson V. 1952. Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. Journal of Bacteriology64, 489–499.

Tang J, Wang C, Feng Y, Yang W, Song H, Chen Z, Yu H, Pan X, Zhou X, Wang H, Wu B, Wang H, Zhao H, Lin Y, Yue J, Wu Z, He X, Gao F, Khan A H, Wang J, et al. 2006. Streptococcal toxic shock syndrome caused by Streptococcus suis serotype 2. PLoS Medicine3, e151.

Toutain P L, Pelligand L, Lees P, Bousquet-Mélou A, Ferran A A, Turnidge J D. 2021. The pharmacokinetic/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: Recent advances and critical appraisal. Journal of Veterinary Pharmacology and Therapeutics44, 172–200.

Wang C Z, Wang M G, Chu Y F, Sun R Y, Li J G, Li X A, Sun J, Liu Y H, Zhou Y F, Liao X P. 2023. Antibiotic resistance patterns and molecular characterization of Streptococcus suis Isolates from swine and humans in China. Microbiology Spectrum11, e0030923.

Wang R L, Liu P, Chen X F, Yao X, Liao X P, Liu Y H, Sun J, Zhou Y F. 2022. Pharmacodynamic target assessment and PK/PD cutoff determination for gamithromycin against Streptococcus suis in piglets. Frontiers in Veterinary Science9, 945632.

Wei X Y, Zhang J, Zhang Y, Fu W Z, Zhong L G, Pan Y D, Sun J, Liao X P, Liu Y H, Zhou Y F. 2024. Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis. BMC Veterinary Research20, 147.

Weng Z, Zeng F, Wang M, Guo S, Tang Z, Itagaki K, Lin Y, Shen X, Cao Y, Duan J A, Wang F. 2023. Antimicrobial activities of lavandulylated flavonoids in Sophora flavences against methicillin-resistant Staphylococcus aureus via membrane disruption. Journal of Advanced Research57, 197–212.

Wertheim H F, Nghia H D, Taylor W, Schultsz C. 2009. Streptococcus suis: An emerging human pathogen. Clinical Infectious Diseases48, 617–625.

Wyns H, Meyer E, Plessers E, Watteyn A, De Baere S, De Backer P, Croubels S. 2014. Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in pigs. Research in Veterinary Science96, 160–163.

Xia X, Qin W, Zhu H, Wang X, Jiang J, Hu J. 2019. How Streptococcus suis serotype 2 attempts to avoid attack by host immune defenses. Journal of MicrobiologyImmunologyand Infection52, 516–525.

Yang B, Tong Z, Shi J, Wang Z, Liu Y. 2023. Bacterial proton motive force as an unprecedented target to control antimicrobial resistance. Medicinal Research Reviews43, 1068–1090.

Yang Q, Liu X, Zhang C, Yong K, Clifton A C, Ding H, Liu Y. 2019. Pharmacokinetics and pharmacodynamics of gamithromycin treatment of Pasteurella multocida in a murine lung infection model. Frontiers in Pharmacology10, 1090.

Yoshida M, Reyes S G, Tsuda S, Horinouchi T, Furusawa C, Cronin L. 2017. Time-programmable drug dosing allows the manipulation, suppression and reversal of antibiotic drug resistance in vitroNature Communications8, 15589.

Yu H, Jing H, Chen Z, Zheng H, Zhu X, Wang H, Wang S, Liu L, Zu R, Luo L, Xiang N, Liu H, Liu X, Shu Y, Lee S S, Chuang S K, Wang Y, Xu J, Yang W. 2006. Human Streptococcus suis outbreak, Sichuan, China. Emerging Infectious Diseases12, 914–920.

Zhao Z, Wen S, Song N, Wang L, Zhou Y, Deng X, Wu C, Zhang G, Chen J, Tian G B, Liang M, Zhong L L. 2023. Arginine-enhanced antimicrobial activity of nanozymes against gram-negative bacteria. Advanced Healthcare Materials13, e2301332.

Zheng C, Wei M, Jia M, Cao M. 2020. Involvement of various enzymes in the physiology and pathogenesis of Streptococcus suisVeterinary Sciences7, 143.

Zhou Y F, Bu M X, Liu P, Sun J, Liu Y H, Liao X P. 2020. Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets. BMC Veterinary Research16, 81.

No related articles found!
No Suggested Reading articles found!